Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
13.44
-0.34 (-2.47%)
Jun 20, 2025, 4:00 PM - Market closed
Niagen Bioscience Stock Forecast
Stock Price Forecast
The 3 analysts that cover Niagen Bioscience stock have a consensus rating of "Strong Buy" and an average price target of $16.67, which forecasts a 24.03% increase in the stock price over the next year. The lowest target is $11 and the highest is $23.
Price Target: $16.67 (+24.03%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Niagen Bioscience stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|
| Strong Buy | 1 | 2 | 3 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $13 → $16 | Strong Buy | Maintains | $13 → $16 | +19.05% | Jun 10, 2025 |
| Roth Capital | Roth Capital | Strong Buy Maintains $10 → $23 | Strong Buy | Maintains | $10 → $23 | +71.13% | Jun 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | -3.27% | May 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | -18.15% | Apr 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | -18.15% | Mar 31, 2025 |
Financial Forecast
Revenue This Year
125.70M
from 99.60M
Increased by 26.21%
Revenue Next Year
151.98M
from 125.70M
Increased by 20.91%
EPS This Year
0.14
from 0.11
Increased by 29.82%
EPS Next Year
0.25
from 0.14
Increased by 75.71%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 130.7M | 159.7M | 189.7M |
| Avg | 125.7M | 152.0M | 180.9M |
| Low | 119.3M | 142.9M | 170.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 31.3% | 27.1% | 24.8% |
| Avg | 26.2% | 20.9% | 19.1% |
| Low | 19.8% | 13.7% | 12.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.24 | 0.37 | 0.41 |
| Avg | 0.14 | 0.25 | 0.37 |
| Low | 0.08 | 0.17 | 0.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 119.5% | 157.4% | 63.2% |
| Avg | 29.8% | 75.7% | 48.4% |
| Low | -28.7% | 16.7% | 32.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.